RESUMO
Objectives: This study was to investigate whether long-term amlodipine-based combination therapy attenuates seasonal variation of office blood pressure (BP) in hypertensive patients. Methods: The data of 206 patients recruited in the Nanchang site of CHIEF trial were retrospectively analyzed. All patients received an amlodipine-based therapy for three years after reaching target BP with a 12-week titration treatment. Among them, 106 patients received amlodipine plus amiloride/hydrochlorothiazide (AA group) and 100 received amlodipine plus telmisartan (AT group) therapies. These patients were followed up every three months . The difference between the highest and lowest values of outdoor temperature in each three months was calculated as the seasonal temperature difference (T-d) and seasonal BP difference was calculated in the similar way. BP control rates in each season were calculated. Results: In the three years, the highest SBP and DBP values occurred in winter and the lowest values in summer. As a result, the BP control rate in summer was the highest and that in winter was the lowest, especially for SBP. Although T-d levels were similar during three following-up years, the seasonal SBP/DBP differences in 2011 were significantly lower than 2009 (10.03 ± 5.74/6.96 ± 3.72 vs 14.36 ± 8.19/9.78 ± 5.21 mmHg, P < .05), suggesting seasonal variation in BP was obviously reduced. Meanwhile, similar change was observed in AA and AT groups. Conclusions: Besides lower BP effectively, long-term amlodipine-based combination therapy could alleviate the seasonal BP variation in high-risk hypertensive patients.
Assuntos
Hipertensão , Anlodipino/farmacologia , Anlodipino/uso terapêutico , Anti-Hipertensivos/farmacologia , Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea , Quimioterapia Combinada , Humanos , Hipertensão/tratamento farmacológico , Estudos Retrospectivos , Estações do Ano , Resultado do TratamentoRESUMO
Interleukin (IL)-38 is the tenth member of the IL-1 cytokine family. IL-38 shares high similarity with IL-36Ra and IL-1Ra and can bind to their receptors, thus exerting an anti-inflammatory effect. Despite the lack of a signal peptide, IL-38 can be released from several cell types, but its maturation process remains obscure. The role of IL-38 in numerous inflammatory diseases, especially in autoimmune diseases, has been extensively studied. In this review, we discuss the characteristics, biological functions and pathways of IL-38, as well as its role in several chronic inflammatory diseases. Better understanding the role of IL-38 will pave the way for clinical treatments in the near future.